New sites at Darmstadt and Hamburg complement company's global integrated mRNA service network with pre-clinical to commercial capabilities
Company's Millipore® CTDMO Services now encompass all key stages of mRNA technologies, lipids, lipid nanoparticles (LNP) and fill/finish, including key products and biosafety testing
Expansion part of company's ongoing € 1 billion investment plan to advance mRNA technologies
